Our findings provide the evidences that the TwHF-based prescription, CRT may be the promising candidate drugs for the treatment of DKD via reversing the imbalance of Immune-Inflammation system which is mediated by PI3K/AKT/NF-кB/IL-1β/TNF-α signaling during the disease progression. This evidence concerns the gene AKT1 and diabetic kidney disease.